Inimmune Welcomes Dr. Heather Madsen of Hatteras Venture Partners to Board of Directors
Missoula, MT, February 28, 2025 – Inimmune Corporation, a clinical-stage biotechnology company specializing in next-generation immunotherapies, is pleased to announce the appointment of Dr. Heather Madsen to its Board of Directors. Dr. Madsen, a distinguished life sciences executive and Operating Partner at Hatteras Venture Partners, brings extensive expertise in the creation of high-performing life science […]
Inimmune to present successful Phase I allergy trial results at the American Academy of Allergy Asthma & Immunology meeting in San Diego, February 28-March 3, 2025
Missoula, MT, February 26, 2025 – Inimmune Corporation, a clinical-stage biotechnology company specializing in next-generation immunotherapies for cancer, allergy, autoimmunity, and vaccines will attend the AAAAI meeting in San Diego from February 28-March 3 where Dr. Jay Evans, Inimmune’s Chief Scientific and Strategy Officer, will provide an update on Inimmune’s clinical stage treatment for seasonal […]
